Greenwich Lifesciences Stock Revenue
| GLSI Stock | USD 11.09 0.15 1.37% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Greenwich Lifesciences' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year |
Greenwich | Revenue | Build AI portfolio with Greenwich Stock |
Greenwich Lifesciences Company Revenue Analysis
Greenwich Lifesciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Greenwich
Projected quarterly revenue analysis of Greenwich Lifesciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Greenwich Lifesciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Greenwich Lifesciences' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Greenwich Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Greenwich Lifesciences reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Greenwich Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenwich Lifesciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenwich Lifesciences could also be used in its relative valuation, which is a method of valuing Greenwich Lifesciences by comparing valuation metrics of similar companies.Greenwich Lifesciences is currently under evaluation in revenue category among its peers.
Greenwich Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Greenwich Lifesciences from analyzing Greenwich Lifesciences' financial statements. These drivers represent accounts that assess Greenwich Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Greenwich Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 434.6M | 287.7M | 182.8M | 128.2M | 142.1M | 226.3M |
Greenwich Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Greenwich Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Greenwich Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
Greenwich Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in Greenwich Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Greenwich Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Greenwich Lifesciences' value.| Shares | Bank Of New York Mellon Corp | 2025-03-31 | 11.2 K | Rhumbline Advisers | 2025-03-31 | 9.7 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 9.5 K | Barclays Plc | 2025-03-31 | 6.6 K | New York State Common Retirement Fund | 2025-03-31 | 6 K | Bank Of America Corp | 2025-03-31 | 5.4 K | Citigroup Inc | 2025-03-31 | 4.3 K | Mirae Asset Global Etfs Holdings Ltd. | 2025-03-31 | 3.6 K | Ubs Group Ag | 2025-03-31 | 3.2 K | Blackrock Inc | 2025-03-31 | 352.2 K | Vanguard Group Inc | 2025-03-31 | 270.3 K |
Greenwich Fundamentals
| Return On Equity | -5.15 | ||||
| Return On Asset | -2.54 | ||||
| Current Valuation | 146.44 M | ||||
| Shares Outstanding | 13.37 M | ||||
| Shares Owned By Insiders | 52.30 % | ||||
| Shares Owned By Institutions | 9.46 % | ||||
| Number Of Shares Shorted | 1 M | ||||
| Price To Book | 113.69 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.79 M) | ||||
| Cash And Equivalents | 15.64 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.56 M | ||||
| Current Ratio | 65.74 X | ||||
| Book Value Per Share | 0.1 X | ||||
| Cash Flow From Operations | (7.27 M) | ||||
| Short Ratio | 18.04 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 39.0 | ||||
| Beta | 3.16 | ||||
| Market Capitalization | 148.25 M | ||||
| Total Asset | 4.09 M | ||||
| Retained Earnings | (66.15 M) | ||||
| Working Capital | 2.53 M | ||||
| Net Asset | 4.09 M |
About Greenwich Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Greenwich Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Greenwich Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Greenwich Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Greenwich Lifesciences Piotroski F Score and Greenwich Lifesciences Altman Z Score analysis. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.